Should I Buy QNRX? QNRX 2026 Analysis

Should You Buy Quoin Pharmaceuticals Ltd (QNRX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

8.300

1 Day change

-8.79%

52 Week Range

41.800

Analysis Updated At

2026/01/26

Quoin Pharmaceuticals Ltd (QNRX) is not a strong buy at the moment for a beginner, long-term investor. While the stock shows potential due to its pipeline developments and regulatory designations, the financial performance remains weak, and technical indicators suggest caution. The lack of strong trading signals and neutral sentiment from insiders and hedge funds further supports a hold recommendation.

Technical Analysis

The MACD histogram is negative (-0.279) and contracting, indicating bearish momentum. The RSI at 17.496 suggests the stock is oversold. Moving averages are converging, showing indecision in price movement. Key support is at 9.637, and resistance is at 11.107. The stock is trading below its pivot level, indicating weakness.

Options Data

Positive Catalysts

Quoin Pharmaceuticals has filed for Breakthrough Medicine Designation for QRX003 with the Saudi Food and Drug Authority. QRX003 has received Orphan Drug and Pediatric Rare Disease Designations from the U.S. FDA and Orphan Drug Designation from the European Medicines Agency. If approved, QRX003 will be the first treatment for Netherton Syndrome globally, supported by a distribution partnership with Genpharm.

Neutral/Negative Catalysts

EPS has dropped significantly (-58.81% YoY). Technical indicators show bearish momentum, and there are no strong trading trends or signals from insiders or hedge funds.

Financial Performance

In Q3 2025, revenue remained at 0 with no growth. Net income improved by 68.02% YoY but remains negative at -$3,948,165. EPS dropped by -58.81% YoY to -6.71, indicating poor profitability. Gross margin remains at 0, showing no operational efficiency.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target data available.

1 Analyst Rating

Wall Street analysts forecast QNRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QNRX is 70 USD with a low forecast of 70 USD and a high forecast of 70 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 9.100

Low

Averages

High